DK1754469T3 - Injicérbare opslemninger med forbedrede injektionsegenskaber - Google Patents

Injicérbare opslemninger med forbedrede injektionsegenskaber Download PDF

Info

Publication number
DK1754469T3
DK1754469T3 DK06010734.9T DK06010734T DK1754469T3 DK 1754469 T3 DK1754469 T3 DK 1754469T3 DK 06010734 T DK06010734 T DK 06010734T DK 1754469 T3 DK1754469 T3 DK 1754469T3
Authority
DK
Denmark
Prior art keywords
injection
viscosity
microparticles
suspension
polysorbate
Prior art date
Application number
DK06010734.9T
Other languages
English (en)
Inventor
Stephan E Zale
Joyce M Hotz
J Michael Ramstack
M Gary Riley
Olufunmi L Johnson
Original Assignee
Alkermes Controlled Therapeutics Inc
Alkermes Pharma Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24310496&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1754469(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alkermes Controlled Therapeutics Inc, Alkermes Pharma Ireland Ltd filed Critical Alkermes Controlled Therapeutics Inc
Application granted granted Critical
Publication of DK1754469T3 publication Critical patent/DK1754469T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Claims (18)

1. Sammensætning egnet til injektion gennem en nål med en diameter i området fra 0,838 mm til 0,412 mm (str. 18-22) i en vært, omfattende mikropartikler, der omfatter et biologisk aktivt middel spredt eller opløst inde i et polymerbindemid-del i et vandigt injektionsbæremedium, hvori (a) mikropartiklerne er opslemmet i injektionsbæremediet i en koncentration større end 30 mg/ml til dannelse af en opslemning og med en middel massediameter på mindst 10 pm og mindre end 250 pm, (b) en flydende fase af opslemningen har en viskositet på mindst 50 cP ved 20s C, (c) det biologisk aktive middel er et peptid, (d) polymerbindemidlet er valgt fra gruppen bestående af poly(glykolsyre), poly-D,L-mælkesyre, poly-L-mælkesyre, og copolymerer af de foregående, og (e) det vandige injektionsbæremedium omfatter (i) et viskositetsforhøjende middel valgt blandt natriumkarboxymetylcellulose, polyvinylpyrrolidon og hydro-xypropylmetylcellulose; (ii) en tonicitetsjusteringsmiddel omfattende natriumklorid; og (iii) et befugtningsmiddel valgt blandt polysorbat 20, polysorbat 40 og po-lysorbat 80, men er ikke det vandige bæremedium bestående af 3 vol-% natriumkarboxymetylcellulose, 1 vol-% polysorbat 20, 0,9 vol-% natriumklorid, og en resterende volumenprocentdel vand.
2. Sammensætning ifølge krav 1, hvori mikropartiklerne har en middel massediameter i området fra 20 pm til 150 pm.
3. Sammensætning ifølge ethvert foregående krav, hvori injektionsbæremediet omfatter sorbitol som et tæthedsforhøjende element.
4. Sammensætning ifølge ethvert foregående krav, hvori viskositeten af opslem-ningens flydende fase er større end 50 cP og mindre end 60 cP ved 20°C.
5. Sammensætning ifølge ethvert foregående krav, hvori injektionsbæremediet omfatter 1,5% natriumkarboxymetylcellulose, 30% sorbitol og 0,2% polysorbat 20.
6. Sammensætning ifølge ethvert foregående krav, hvori injektionsbæremediet omfatter 3% natriumkarboxymetylcellulose, 0,9% saltvand og 0,1% polysorbat 20.
7. Sammensætning ifølge ethvert foregående krav, hvori polymerbindemidlet er poly (D, L-lakt id-co-gly kolid).
8. Sammensætning ifølge krav 7, hvori polymerbindemidlet er poly(D,L-laktid-co-glykolid) med et molforhold af laktid til glykolid i intervallet fra 85:15 til 50:50.
9. Anvendelse af en sammensætning ifølge ethvert foregående krav til fremstilling af et medikament til injektion i en vært gennem en nål med diameter i området fra 0,838 mm til 0,412 mm (str. 18-22).
10. Sammensætning ifølge ethvert foregående krav til injektion i en vært gennem en nål med diameter i området fra 0,838 mm til 0,412 mm (str. 18-22).
11. Fremgangsmåde til fremstilling af en sammensætning egnet til injektion gennem en nål med en diameter i området fra 0,838 mm til 0,412 mm (str. 18-22) i en vært, omfattende: (a) tilvejebringelse af mikropartikler omfattende et biologisk aktivt middel spredt eller opløst i et polymerbindemiddel, hvilke mikropartikler har en middel massediameter på mindst 10 pm og mindre end 250 pm, (b) tilvejebringelse af et vandigt injektionsbæremedium med en viskositet på mindst 50 cP ved 20SC, og (c) opslemning af mikropartiklerne i det vandige injektionsbæremedium i en koncentration større end 30 mg/ml til dannelse af en opslemning, hvori (i) det biologisk aktive middel er et peptid, (ii) polymerbindemidlet er valgt fra gruppen bestående af po-ly(glykolsyre), poly-D,L-mælkesyre, poly-L-mælkesyre, og copolymerer af de foregående, og (iii) det vandige injektionsbæremedium omfatter (i) et viskositetsforhøjende middel valgt blandt natriumkarboxymetylcellulose, polyvinylpyrroli-don og hydroxypropylmetylcellulose; (ii) en tonicitetsjusteringsmiddel omfattende natriumklorid; og (iii) et befugtningsmiddel valgt blandt poly-sorbat 20, polysorbat 40 og polysorbat 80, men er ikke det vandige bæremedium bestående af 3 vol-% natriumkarboxymetylcellulose, 1 vol-% polysorbat 20, 0,9 vol-% natriumklorid, og en resterende volumenprocentdel vand.
12. Fremgangsmåde ifølge krav 11, hvori mikropartiklerne har en middel massediameter i området fra 20 gm til 150 gm.
13. Fremgangsmåde ifølge krav 11 eller 12, hvori injektionsbæremediet omfatter sorbitol som et tæthedsforhøjende element.
14. Fremgangsmåde ifølge ethvert af krav 11-13, hvori viskositeten af opslemnin-gens flydende fase er større end 50 cP og mindre end 60 cP ved 20°C.
15. Fremgangsmåde ifølge ethvert af krav 11-14, hvori injektionsbæremediet omfatter 1,5% natriumkarboxymetylcellulose, 30% sorbitol og 0,2% polysorbat 20.
16. Fremgangsmåde ifølge ethvert af krav 11-14, hvori injektionsbæremediet omfatter 3% natriumkarboxymetylcellulose, 0,9% saltvand og 0,1% polysorbat 20.
17. Fremgangsmåde ifølge ethvert af krav 11-16, hvori polymerbindemidlet er poly (D, L- lakt id-co-gly kolid).
18. Fremgangsmåde ifølge krav 17, hvori polymerbindemidlet er poly(D,L-laktid-co-glykolid) med et molforhold af laktid til glykolid i intervallet fra 85:15 til 50:50.
DK06010734.9T 2000-05-25 2001-04-19 Injicérbare opslemninger med forbedrede injektionsegenskaber DK1754469T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/577,875 US6495164B1 (en) 2000-05-25 2000-05-25 Preparation of injectable suspensions having improved injectability
EP01928628A EP1283699B1 (en) 2000-05-25 2001-04-19 Injectable suspensions having improved injectability properties

Publications (1)

Publication Number Publication Date
DK1754469T3 true DK1754469T3 (da) 2016-06-27

Family

ID=24310496

Family Applications (3)

Application Number Title Priority Date Filing Date
DK06010734.9T DK1754469T3 (da) 2000-05-25 2001-04-19 Injicérbare opslemninger med forbedrede injektionsegenskaber
DK10174743.4T DK2269577T3 (da) 2000-05-25 2001-04-19 Injicerbare suspensioner med forbedrede injiceringsegenskaber.
DK01928628T DK1283699T3 (da) 2000-05-25 2001-04-19 Fremstilling af injicerbare suspensioner med forbedrede indspröjtningsegenskaber

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK10174743.4T DK2269577T3 (da) 2000-05-25 2001-04-19 Injicerbare suspensioner med forbedrede injiceringsegenskaber.
DK01928628T DK1283699T3 (da) 2000-05-25 2001-04-19 Fremstilling af injicerbare suspensioner med forbedrede indspröjtningsegenskaber

Country Status (27)

Country Link
US (7) US6495164B1 (da)
EP (4) EP1283699B1 (da)
JP (1) JP4502355B2 (da)
KR (1) KR100810480B1 (da)
CN (1) CN100453067C (da)
AT (1) ATE363891T1 (da)
AU (2) AU2001255463B2 (da)
BG (1) BG66023B1 (da)
BR (1) BRPI0111060B8 (da)
CA (1) CA2406536C (da)
CY (3) CY1107441T1 (da)
CZ (1) CZ301359B6 (da)
DE (1) DE60128798T2 (da)
DK (3) DK1754469T3 (da)
ES (3) ES2286118T3 (da)
HK (4) HK1054319A1 (da)
HU (1) HU228587B1 (da)
IL (1) IL152767A (da)
IS (1) IS2471B (da)
MX (1) MXPA02011543A (da)
NO (1) NO334660B1 (da)
NZ (1) NZ522335A (da)
PL (1) PL204298B1 (da)
PT (2) PT1283699E (da)
RU (1) RU2002135641A (da)
SI (2) SI2269577T1 (da)
WO (1) WO2001091720A2 (da)

Families Citing this family (135)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
US6770478B2 (en) * 2000-02-10 2004-08-03 The Regents Of The University Of California Erythrocytic cells and method for preserving cells
US6495164B1 (en) * 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
US6824822B2 (en) 2001-08-31 2004-11-30 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
US7758890B2 (en) 2001-06-23 2010-07-20 Lyotropic Therapeutics, Inc. Treatment using dantrolene
KR100525189B1 (ko) * 2002-10-10 2005-10-31 메디칸(주) 고체를 이용한 생체 부피 대체를 위한 주사용 소재
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
JP5591434B2 (ja) * 2002-12-20 2014-09-17 ゼリス ファーマシューティカルズ インコーポレイテッド 皮内注射方法
WO2004064752A2 (en) * 2003-01-22 2004-08-05 Alkermes Controlled Therapeutics, Inc. Method of preparing sustained release microparticles
EP1603513B1 (en) * 2003-03-04 2020-12-30 Lyotropic Therapeutics, Inc. Dantrolene compositions
WO2004103342A2 (en) * 2003-05-16 2004-12-02 Alkermes Controlled Therapeutics, Inc. Injectable sustained release compositions
US20050032811A1 (en) * 2003-08-06 2005-02-10 Josiah Brown Methods for administering aripiprazole
US7169180B2 (en) * 2003-09-03 2007-01-30 Brennan William A System and method for breast augmentation
DK1660009T3 (da) * 2003-09-03 2015-04-27 Miscon Trading S A Fremgangsmåder til behandling af endometriose
US8092527B2 (en) * 2003-09-03 2012-01-10 Brennan William A System and method for breast augmentation
US20050064045A1 (en) * 2003-09-18 2005-03-24 Sheng-Ping Zhong Injectable therapeutic formulations
US7906125B2 (en) * 2003-09-18 2011-03-15 Boston Scientific Scimed, Inc. Solid or semi-solid therapeutic formulations
ES2315721T5 (es) * 2003-10-23 2012-08-24 Otsuka Pharmaceutical Co., Ltd. Formulación de aripiprazol inyectable estéril de liberación controlada y procedimiento
KR101144647B1 (ko) * 2003-10-31 2012-05-08 와카모토 세이야꾸 가부시끼가이샤 가역성 열 겔화 수성 조성물
EP2409707B8 (en) 2004-04-15 2015-05-06 Alkermes Pharma Ireland Limited Polymer-based sustained release device
US20060110423A1 (en) * 2004-04-15 2006-05-25 Wright Steven G Polymer-based sustained release device
US7456254B2 (en) * 2004-04-15 2008-11-25 Alkermes, Inc. Polymer-based sustained release device
WO2005107714A2 (en) * 2004-05-05 2005-11-17 Alkermes Controlled Therapeutics, Inc. Method of forming microparticles that include a bisphosphonate and a polymer
ES2309766T3 (es) * 2004-06-04 2008-12-16 Camurus Ab Formulaciones liquidas de liberacion lenta.
ITMI20041245A1 (it) * 2004-06-22 2004-09-22 Ibsa Inst Biochimique Sa Composizioni farmaceutiche iniettabnili comprendenti diclofenac sodico e b-ciclodestrina
EP1679065A1 (en) * 2005-01-07 2006-07-12 OctoPlus Sciences B.V. Controlled release compositions for interferon based on PEGT/PBT block copolymers
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
US8318210B2 (en) * 2005-02-28 2012-11-27 Neos Therapeutics, Lp Compositions and methods of making sustained release liquid formulations
US7862552B2 (en) 2005-05-09 2011-01-04 Boston Scientific Scimed, Inc. Medical devices for treating urological and uterine conditions
US8263109B2 (en) * 2005-05-09 2012-09-11 Boston Scientific Scimed, Inc. Injectable bulking compositions
US20060251581A1 (en) * 2005-05-09 2006-11-09 Mcintyre Jon T Method for treatment of uterine fibroid tumors
PL3524261T3 (pl) 2005-08-19 2024-04-15 Amylin Pharmaceuticals, Llc Eksendyna do stosowania w leczeniu cukrzycy i zmniejszania masy ciała
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
CN103071209A (zh) 2005-11-17 2013-05-01 周吉尼克斯股份有限公司 用无针注射递送粘稠制剂
US20090038701A1 (en) 2006-01-17 2009-02-12 Baxter International Inc. Device, system and method for mixing
EP2020990B1 (en) 2006-05-30 2010-09-22 Intarcia Therapeutics, Inc Two-piece, internal-channel osmotic delivery system flow modulator
AU2007284759B2 (en) 2006-08-09 2010-10-28 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
JP4941977B2 (ja) * 2007-04-11 2012-05-30 大蔵製薬株式会社 ベンズイソキサゾール誘導体の経口ゼリー状医薬組成物
AU2008244523B2 (en) 2007-04-23 2012-02-16 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
BRPI0811319A2 (pt) 2007-05-25 2015-02-10 Tolmar Therapeutics Inc Composição fluida, método de formação de uma composição fluida, implante biodegrádavel formado in situ, método de formação de um implante biodegradável in situ, kit, implante e método de trataento
US10092524B2 (en) 2008-06-11 2018-10-09 Edge Therapeutics, Inc. Compositions and their use to treat complications of aneurysmal subarachnoid hemorrhage
CN101842084B (zh) * 2007-07-26 2014-11-05 亚克蒂斯Ip有限公司 包含pcl的微粒及其用途
PT2170279T (pt) * 2007-07-31 2018-04-06 Otsuka Pharma Co Ltd Métodos para produção de suspensão de aripiprazole e formulação liofilizada
WO2009056990A2 (en) * 2007-08-21 2009-05-07 Actavis Group Ptc Ehf Paliperidone polymorphs
US9987221B2 (en) * 2007-08-23 2018-06-05 Boston Scientific Scimed, Inc. Injectable hydrogel compositions
JP2011502990A (ja) * 2007-11-05 2011-01-27 ボーシュ アンド ローム インコーポレイティド 薬物送達用ビヒクルとしての水非混和性物質
EP2240155B1 (en) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Devices, formulations, and methods for delivery of multiple beneficial agents
CN102014625A (zh) 2008-04-28 2011-04-13 佐吉尼克斯股份有限公司 用于治疗偏头痛的新制剂
EP2303313B1 (en) 2008-05-21 2015-10-28 Amylin Pharmaceuticals, LLC Exendins to lower cholestrol and triglycerides
EA020753B1 (ru) 2008-06-16 2015-01-30 Бинд Терапьютикс, Инк. Терапевтические полимерные наночастицы, содержащие алкалоиды vinca, и их применение
JP6363320B2 (ja) 2008-06-16 2018-07-25 ファイザー・インク 薬剤を装填したポリマーナノ粒子及びその製造方法と使用方法
WO2010005726A2 (en) * 2008-06-16 2010-01-14 Bind Biosciences Inc. Therapeutic polymeric nanoparticles with mtor inhibitors and methods of making and using same
US9216152B2 (en) 2008-06-27 2015-12-22 Tepha, Inc. Injectable delivery of microparticles and compositions therefore
BRPI0918904B8 (pt) 2008-09-04 2021-05-25 Amylin Pharmaceuticals Inc formulação pré-misturada fabricada para injeção, seu uso e kit compreendendo a mesma
US20100063879A1 (en) * 2008-09-05 2010-03-11 Yellowpages.Com Llc Systems and Methods to Selectively Provide Information Based on User Interest
US8563041B2 (en) 2008-12-12 2013-10-22 Bind Therapeutics, Inc. Therapeutic particles suitable for parenteral administration and methods of making and using same
WO2010075072A2 (en) 2008-12-15 2010-07-01 Bind Biosciences Long circulating nanoparticles for sustained release of therapeutic agents
RU2547990C2 (ru) 2009-09-28 2015-04-10 Интарсия Терапьютикс, Инк. Быстрое достижение и/или прекращение существенной стабильной доставки лекарственного средства
TR201906255T4 (tr) 2009-12-11 2019-05-21 Pfizer Terapötik partiküllerin liyofilize edilmesine yönelik stabil formülasyonlar.
EP2515942B1 (en) 2009-12-15 2020-02-12 Pfizer Inc. Therapeutic polymeric nanoparticle compositions with high glass transition temperature or high molecular weight copolymers
US8889193B2 (en) 2010-02-25 2014-11-18 The Johns Hopkins University Sustained delivery of therapeutic agents to an eye compartment
US20120046225A1 (en) 2010-07-19 2012-02-23 The Regents Of The University Of Colorado, A Body Corporate Stable glucagon formulations for the treatment of hypoglycemia
WO2012039979A2 (en) 2010-09-10 2012-03-29 The Johns Hopkins University Rapid diffusion of large polymeric nanoparticles in the mammalian brain
CA2814840C (en) 2010-10-18 2018-08-28 Dainippon Sumitomo Pharma Co., Ltd. Sustained-release formulation for injection
US9327037B2 (en) 2011-02-08 2016-05-03 The Johns Hopkins University Mucus penetrating gene carriers
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
AU2012225268B2 (en) 2011-03-10 2016-10-20 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of peptide drugs
US9138479B2 (en) 2011-10-31 2015-09-22 Xeris Pharmaceuticals, Inc. Formulations for the treatment of diabetes
CA2863632C (en) 2012-01-19 2017-07-11 The Johns Hopkins University Nanoparticle formulations with enhanced mucosal penetration
US10159743B2 (en) 2012-03-16 2018-12-25 The Johns Hopkins University Non-linear multiblock copolymer-drug conjugates for the delivery of active agents
EP2825206A1 (en) 2012-03-16 2015-01-21 The Johns Hopkins University Controlled release formulations for the delivery of hif-1 inhibitors
US11596599B2 (en) 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
EP2844295A1 (en) 2012-05-03 2015-03-11 Kala Pharmaceuticals, Inc. Pharmaceutical nanoparticles showing improved mucosal transport
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
WO2013166408A1 (en) 2012-05-03 2013-11-07 Kala Pharmaceuticals, Inc. Pharmaceutical nanoparticles showing improved mucosal transport
JP6392209B2 (ja) 2012-05-04 2018-09-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 粘液内層を通過する迅速な透過のための脂質ベース薬物キャリア
US9125805B2 (en) 2012-06-27 2015-09-08 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of small molecule drugs
EP2877155B1 (en) 2012-07-26 2020-10-28 Camurus AB Opioid formulations
AU2013315118B2 (en) 2012-09-17 2017-10-05 Pfizer Inc. Process for preparing therapeutic nanoparticles
US10568975B2 (en) 2013-02-05 2020-02-25 The Johns Hopkins University Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof
US9018162B2 (en) 2013-02-06 2015-04-28 Xeris Pharmaceuticals, Inc. Methods for rapidly treating severe hypoglycemia
RU2016136430A (ru) * 2014-02-11 2018-03-15 Др. Редди'С Лабораторис Лтд. Парентеральные композиции целекоксиба
WO2015127389A1 (en) 2014-02-23 2015-08-27 The Johns Hopkins University Hypotonic enema formulations and methods of use
EP3116547B1 (en) 2014-03-14 2019-06-05 Pfizer Inc Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same
WO2016022831A1 (en) 2014-08-06 2016-02-11 Xeris Pharmaceuticals, Inc. Syringes, kits, and methods for intracutaneous and/or subcutaneous injection of pastes
US11504322B2 (en) 2014-08-28 2022-11-22 The General Hospital Corporation Injectable slurries and methods of manufacturing the same
US11471401B2 (en) 2014-08-28 2022-10-18 The General Hospital Corporation Injectable slurries and methods of manufacturing the same
BR112017003143B1 (pt) 2014-08-28 2023-12-05 The General Hospital Corporation Suspensões injetáveis, métodos para fabricação das mesmas e seus usos
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
CN117398350A (zh) 2014-12-15 2024-01-16 约翰霍普金斯大学 舒尼替尼制剂及其在治疗青光眼中的使用方法
CA2974715C (en) 2015-01-27 2020-05-05 The Johns Hopkins University Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces
US20160303281A1 (en) 2015-04-17 2016-10-20 Rochal Industries, Llc Composition and kits for pseudoplastic microgel matrices
US10639354B2 (en) 2015-05-22 2020-05-05 The Bot Of The Leland Stanford Junior University Treatment of hyperinsulinemic hypoglycemia with exendin (9-39)
EP3302354B1 (en) 2015-06-03 2023-10-04 i2o Therapeutics, Inc. Implant placement systems
US9649364B2 (en) 2015-09-25 2017-05-16 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic formulations in aprotic polar solvents
CA2987209A1 (en) 2015-06-10 2016-12-15 Evonik Rohm Gmbh Process for preparing a powder comprising a human coagulation factor protein and a lactic acid polymer
EP3340982B1 (en) 2015-08-26 2021-12-15 Achillion Pharmaceuticals, Inc. Compounds for treatment of immune and inflammatory disorders
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
CN116942677A (zh) 2015-09-21 2023-10-27 梯瓦制药国际有限责任公司 缓释奥氮平制剂
US11590205B2 (en) 2015-09-25 2023-02-28 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents
CN105310980A (zh) * 2015-10-09 2016-02-10 北京万全德众医药生物技术有限公司 帕利哌酮缓释混悬口服液及其制备方法
BR112018009644A2 (pt) 2015-11-12 2018-11-06 Graybug Vision Inc micropartículas agregantes sólidas modificadas na superfície, material injetável, processo para preparação de micropartículas agregantes sólidas modificadas na superfície, método para tratamento de um distúrbio ocular, e, uso de micropartículas agregantes sólidas modificadas na superfície
AU2016355236C1 (en) 2015-11-16 2022-09-22 Medincell A method for morselizing and/or targeting pharmaceutically active principles to synovial tissue
KR20180122642A (ko) 2016-02-26 2018-11-13 더 제너럴 하스피탈 코포레이션 의료용 빙류 슬러리 제조 및 전달 시스템 및 방법
WO2017152014A1 (en) 2016-03-04 2017-09-08 Eiger Biopharmaceuticals, Inc. Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives
WO2017197055A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
CN109562113A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的螺环降解决定子体
EP3455218A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
RU2760007C2 (ru) 2016-05-16 2021-11-22 Интарсия Терапьютикс, Инк. Полипептиды, селективные к рецепторам глюкагона, и способы их применения
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
EP3939591A1 (en) 2016-06-27 2022-01-19 Achillion Pharmaceuticals, Inc. Quinazoline and indole compounds to treat medical disorders
AU2017290748A1 (en) 2016-07-01 2019-01-17 G1 Therapeutics, Inc. Pyrimidine-based antiproliferative agents
EP3515408A1 (en) 2016-09-23 2019-07-31 Delpor, Inc. Stable compositions for incretin mimetic compounds
WO2018094404A1 (en) 2016-11-21 2018-05-24 Eiger Biopharmaceuticals, Inc. Buffered formulations of exendin (9-39)
WO2018129058A1 (en) 2017-01-03 2018-07-12 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a glp-1 receptor agonist and co-adminstration of a drug
US10350200B2 (en) * 2017-01-23 2019-07-16 Southwest Research Institute Aqueous suspensions of oximes for autoinjectors
WO2018151849A1 (en) 2017-02-17 2018-08-23 Privo Technologies, Inc. Particle-based multi-layer therapeutic delivery device and method
EP3600258A1 (en) 2017-03-20 2020-02-05 Teva Pharmaceuticals International GmbH Sustained release olanzapine formulaitons
JP7217022B2 (ja) 2017-03-23 2023-02-02 グレイバグ ビジョン インコーポレイテッド 眼障害の治療のための薬物及び組成物
EP3621654A4 (en) 2017-05-10 2021-02-17 Graybug Vision, Inc. PROLONGED-RELEASE MICROPARTICLES AND SUSPENSIONS OF THESE INTENDED FOR MEDICAL THERAPY
AU2018275686B2 (en) 2017-06-02 2024-02-01 Xeris Pharmaceuticals, Inc. Precipitation resistant small molecule drug formulations
US10568842B2 (en) * 2017-08-18 2020-02-25 Lance L. Gooberman Anti-inflammatory pharmaceutical compositions and methods of administration
CN109589304A (zh) * 2017-10-01 2019-04-09 万特制药(海南)有限公司 利培酮口服溶液及其制备方法
JP2021519337A (ja) 2018-03-26 2021-08-10 シー４ セラピューティクス， インコーポレイテッド Ｉｋａｒｏｓの分解のためのセレブロン結合剤
EP3841086A4 (en) 2018-08-20 2022-07-27 Achillion Pharmaceuticals, Inc. PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF MEDICAL DISORDERS RELATED TO COMPLEMENT FACTOR D
MX2021004027A (es) * 2018-10-15 2021-08-11 Chong Kun Dang Pharmaceutical Corp Composiciones de microparticulas inyectables de naltrexona de accion prolongada.
WO2020081723A1 (en) 2018-10-16 2020-04-23 Georgia State University Research Foundation, Inc. Carbon monoxide prodrugs for the treatment of medical disorders
WO2021138646A1 (en) * 2020-01-03 2021-07-08 Privo Technologies, Inc. Systems and pharmaceutical compositions for treatment by direct injection of a targeted population of cells
BE1028769B1 (nl) * 2020-11-02 2022-05-31 Flanders Color Nv Watergedragen vloeibare spoellak
US20240100012A1 (en) 2021-01-18 2024-03-28 Mark Hasleton Pharmaceutical dosage form
US11241330B1 (en) 2021-04-02 2022-02-08 Brixton Biosciences, Inc. Apparatus for creation of injectable slurry
AU2022308198A1 (en) 2021-07-06 2024-02-01 Mark Hasleton Treatment of serotonin reuptake inhibitor withdrawal syndrome
CN114146020B (zh) * 2022-02-10 2022-04-29 中国远大集团有限责任公司 一种注射美容产品及其制备方法和应用

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL137652C (da) 1962-07-11
BE744162A (fr) 1969-01-16 1970-06-15 Fuji Photo Film Co Ltd Procede d'encapsulage
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
DE2010115A1 (de) 1970-03-04 1971-09-16 Farbenfabriken Bayer Ag, 5090 Leverkusen Verfahren zur Herstellung von Mikrogranulaten
US3700215A (en) * 1970-10-21 1972-10-24 Hardman Inc Mixing and dispensing device
JPS523342B2 (da) 1972-01-26 1977-01-27
GB1413186A (en) 1973-06-27 1975-11-12 Toyo Jozo Kk Process for encapsulation of medicaments
US4029782A (en) * 1975-04-28 1977-06-14 Eli Lilly And Company Cefazolin suspension for parenteral administration
JPS523653A (en) 1975-06-27 1977-01-12 Fuji Photo Film Co Ltd Process for producing fine polymer particles
IL51791A0 (en) * 1976-04-14 1977-05-31 Exxon Research Engineering Co New injectable medicinal compositions
US4384975A (en) 1980-06-13 1983-05-24 Sandoz, Inc. Process for preparation of microspheres
US4389330A (en) 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
US4530840A (en) 1982-07-29 1985-07-23 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
JPS60112713A (ja) * 1983-11-21 1985-06-19 Sumitomo Chem Co Ltd 有用な徐放性注射剤
US5385738A (en) 1983-10-14 1995-01-31 Sumitomo Pharmaceuticals Company, Ltd. Sustained-release injection
JPH0657658B2 (ja) * 1985-04-11 1994-08-03 住友製薬株式会社 徐放性製剤
JPS60100516A (ja) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4804663A (en) 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
IE59361B1 (en) 1986-01-24 1994-02-09 Akzo Nv Pharmaceutical preparation for obtaining a highly viscous hydrogel or suspension
US4803075A (en) * 1986-06-25 1989-02-07 Collagen Corporation Injectable implant composition having improved intrudability
WO1989003678A1 (en) 1987-10-30 1989-05-05 Stolle Research & Development Corporation Low residual solvent microspheres and microencapsulation process
US5158952A (en) 1988-11-07 1992-10-27 Janssen Pharmaceutica N.V. 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use
IL92344A0 (en) 1989-01-04 1990-07-26 Gist Brocades Nv Microencapsulation of bioactive substances in biocompatible polymers,microcapsules obtained and pharmaceutical preparation comprising said microcapsules
US5019400A (en) 1989-05-01 1991-05-28 Enzytech, Inc. Very low temperature casting of controlled release microspheres
ATE133087T1 (de) 1989-05-04 1996-02-15 Southern Res Inst Einkapselungsverfahren
US5478564A (en) 1990-02-22 1995-12-26 Teva Pharmaceutical Industries, Ltd. Preparation of microparticles for controlled release of water-soluble substances
US5271941A (en) * 1990-11-02 1993-12-21 Cho Chung Yoon S Antisense oligonucleotides of human regulatory subunit RI.sub.α of cAMP-dependent protein kinases
IT1243390B (it) 1990-11-22 1994-06-10 Vectorpharma Int Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.
US5486362A (en) * 1991-05-07 1996-01-23 Dynagen, Inc. Controlled, sustained release delivery system for treating drug dependency
HU222501B1 (hu) 1991-06-28 2003-07-28 Endorecherche Inc. MPA-t vagy MGA-t tartalmazó nyújtott hatóanyag-felszabadulású gyógyászati készítmény és eljárás előállítására
US20020009443A1 (en) * 1991-12-02 2002-01-24 Vanitha Ramakrishman Inhibitory immunoglobulin polypeptides to human pdgf beta receptor
US5658593A (en) 1992-01-16 1997-08-19 Coletica Injectable compositions containing collagen microcapsules
US6537574B1 (en) * 1992-02-11 2003-03-25 Bioform, Inc. Soft tissue augmentation material
DE69328677T2 (de) 1992-02-28 2000-08-31 Collagen Corp Hochkonzentrierte homogenisierte kollagenzusammensetzungen
US5656297A (en) 1992-03-12 1997-08-12 Alkermes Controlled Therapeutics, Incorporated Modulated release from biocompatible polymers
WO1993019739A1 (en) 1992-03-30 1993-10-14 Alza Corporation Viscous suspensions of controlled-release drug particles
GB9211268D0 (en) * 1992-05-28 1992-07-15 Ici Plc Salts of basic peptides with carboxyterminated polyesters
PT669128E (pt) * 1992-11-17 2000-06-30 Yoshitomi Pharmaceutical Micro-esfera de libertacao sustentada contendo antipsicoticos e processo para produzir a mesma
ATE195652T1 (de) 1992-12-02 2000-09-15 Alkermes Inc Wachstumhormon enthaltende mikrosphaeren mit kontrollierter freisetzung
US5429824A (en) * 1992-12-15 1995-07-04 Eastman Kodak Company Use of tyloxapole as a nanoparticle stabilizer and dispersant
MY113268A (en) * 1992-12-29 2002-01-31 Insite Vision Incorporated Plasticized bioerodible controlled delivery system
TW376319B (en) 1993-04-28 1999-12-11 Janssen Pharmaceutica Nv Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
ATE212830T1 (de) 1993-11-19 2002-02-15 Alkermes Inc Herstellung biologisch abbaubarer, einen biologisch aktiven stoff enthaltender, mikropartikel
ATE288270T1 (de) 1993-11-19 2005-02-15 Janssen Pharmaceutica Nv Mikroverkapselte 1,2-benzazole
US5650173A (en) 1993-11-19 1997-07-22 Alkermes Controlled Therapeutics Inc. Ii Preparation of biodegradable microparticles containing a biologically active agent
US5453425A (en) 1994-07-11 1995-09-26 Janssen Pharmaceutica N.V. Risperidone oral formulation
DE4440337A1 (de) * 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
US5922253A (en) 1995-05-18 1999-07-13 Alkermes Controlled Therapeutics, Inc. Production scale method of forming microparticles
US5904935A (en) 1995-06-07 1999-05-18 Alza Corporation Peptide/protein suspending formulations
US5747058A (en) 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
US5942241A (en) * 1995-06-09 1999-08-24 Euro-Celtique, S.A. Formulations and methods for providing prolonged local anesthesia
US5942253A (en) * 1995-10-12 1999-08-24 Immunex Corporation Prolonged release of GM-CSF
SE505146C2 (sv) 1995-10-19 1997-06-30 Biogram Ab Partiklar för fördröjd frisättning
ATE508733T1 (de) * 1996-03-04 2011-05-15 Penn State Res Found Materialien und verfahren zur steigerung der zellulären internalisierung
US5792477A (en) * 1996-05-07 1998-08-11 Alkermes Controlled Therapeutics, Inc. Ii Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent
TW487572B (en) * 1996-05-20 2002-05-21 Janssen Pharmaceutica Nv Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
EP1009390A4 (en) 1997-07-02 2004-05-06 Euro Celtique Sa LONG-EFFECT ANESTHESIA INJECTED IN JOINT AND BODY SPACES
GB9718986D0 (en) 1997-09-09 1997-11-12 Danbiosyst Uk Controlled release microsphere delivery system
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
JP2000039867A (ja) * 1998-05-18 2000-02-08 Fujitsu Ltd プラズマディスプレイ装置およびプラズマディスプレイパネルの駆動方法
US6143314A (en) * 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
US6194006B1 (en) * 1998-12-30 2001-02-27 Alkermes Controlled Therapeutics Inc. Ii Preparation of microparticles having a selected release profile
US6306425B1 (en) * 1999-04-09 2001-10-23 Southern Research Institute Injectable naltrexone microsphere compositions and their use in reducing consumption of heroin and alcohol
WO2001015699A1 (en) 1999-08-27 2001-03-08 Southern Research Institute Injectable buprenorphine microparticle compositions and their use
US6495164B1 (en) * 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability

Also Published As

Publication number Publication date
EP1754469A1 (en) 2007-02-21
IL152767A0 (en) 2003-06-24
IS6595A (is) 2002-10-28
BR0111060A (pt) 2003-04-15
HK1056321A1 (en) 2004-02-13
BG107288A (bg) 2003-06-30
HUP0302283A3 (en) 2007-02-28
DE60128798T2 (de) 2007-10-31
EP2269577A3 (en) 2011-11-30
AU2001255463B2 (en) 2004-11-04
US20080044485A1 (en) 2008-02-21
BRPI0111060B1 (pt) 2019-04-16
HK1054319A1 (en) 2003-11-28
EP1283699A2 (en) 2003-02-19
ATE363891T1 (de) 2007-06-15
ES2572877T3 (es) 2016-06-02
DK1283699T3 (da) 2007-10-01
CY1117652T1 (el) 2017-05-17
US20040208938A1 (en) 2004-10-21
AU5546301A (en) 2001-12-11
ES2574823T3 (es) 2016-06-22
HK1103346A1 (zh) 2007-12-21
KR20030020285A (ko) 2003-03-08
CN100453067C (zh) 2009-01-21
EP2269577A2 (en) 2011-01-05
HK1152660A1 (zh) 2012-03-09
RU2002135641A (ru) 2004-07-20
US6667061B2 (en) 2003-12-23
DK2269577T3 (da) 2016-06-27
EP2269577B1 (en) 2016-03-16
WO2001091720A3 (en) 2002-05-23
WO2001091720A2 (en) 2001-12-06
NO334660B1 (no) 2014-05-12
CZ301359B6 (cs) 2010-01-27
DE60128798D1 (de) 2007-07-19
BG66023B1 (bg) 2010-11-30
CA2406536A1 (en) 2001-12-06
SI1754469T1 (sl) 2016-09-30
IS2471B (is) 2008-12-15
CN1430501A (zh) 2003-07-16
ES2286118T3 (es) 2007-12-01
EP3095442B1 (en) 2020-11-18
EP3095442A1 (en) 2016-11-23
NO20025164D0 (no) 2002-10-28
PL204298B1 (pl) 2009-12-31
US7799345B2 (en) 2010-09-21
JP4502355B2 (ja) 2010-07-14
US20140193507A1 (en) 2014-07-10
CY1117734T1 (el) 2017-05-17
IL152767A (en) 2008-12-29
PL365195A1 (en) 2004-12-27
JP2003534366A (ja) 2003-11-18
PT1283699E (pt) 2007-06-22
NO20025164L (no) 2002-11-25
US6495164B1 (en) 2002-12-17
PT2269577E (pt) 2016-06-14
KR100810480B1 (ko) 2008-03-07
US20080044478A1 (en) 2008-02-21
EP1283699B1 (en) 2007-06-06
BRPI0111060B8 (pt) 2021-05-25
US7371406B2 (en) 2008-05-13
CZ20023848A3 (cs) 2003-05-14
HU228587B1 (en) 2013-04-29
US20100303900A1 (en) 2010-12-02
MXPA02011543A (es) 2004-08-12
EP1754469B1 (en) 2016-03-23
CA2406536C (en) 2009-12-22
US20030113380A1 (en) 2003-06-19
CY1107441T1 (el) 2012-12-19
NZ522335A (en) 2003-08-29
SI2269577T1 (sl) 2016-09-30
HUP0302283A2 (hu) 2003-10-28

Similar Documents

Publication Publication Date Title
DK1754469T3 (da) Injicérbare opslemninger med forbedrede injektionsegenskaber
AU2001255463A1 (en) Preparation of injectable suspensions having improved injectability
EP1526835B1 (en) Injectable depot compositions and uses thereof
EP1446101B1 (en) Catheter injectable depot compositions and uses thereof
KR101708517B1 (ko) 일정하게 높은 노출 수준을 갖는 옥트레오티드 데포 제제